This is the authors' abstract. We don't add key points for this paper.
Acute lymphocytic leukemia (ALL) is the most common malignancy in childhood accounting for 35--40% of cancers in this age group. At the time of diagnosis approximately a trillion ( 1012) leukemic cells are present throughout the body (1). The bone marrow has been replaced and sup pressed by leukemic cells causing a cessation of normal blood cell produc tion. Previously both physicians and parents equated a diagnosis of acute lymphocytic leukemia with a certainty of rapid death. This dire prognosis has changed dramatically in the last 20 yeats. Now a complete bone marrow remission can be induced in 95% of children with ALL. Moreover, one half of these children will have a prolonged leukemia-free survival and probable cure. This chapter reviews the therapeutic advances that have led to this great improvement in survival, the current problems associated with this treat ment, and approaches to achieve more specific and effective therapy. Recent articles have summarized the first two topics (1-7), so we concentrate on new directions for therapy. Innovative new approaches are needed since the percentage of patients who achieve long-term leukemia·free survival has not increased appreciably in the last 10 years.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Holcenberg et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: